RecruitingPhase 4NCT05320627

Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Sponsor

China National Center for Cardiovascular Diseases

Enrollment

120 participants

Start Date

Mar 30, 2022

Study Type

INTERVENTIONAL

Conditions

Non Valvular Atrial Fibrillation

Summary

Based on the population pharmacokinetic data of Chinese patients with atrial fibrillation, the study will evaluate the suitability of the ENGAGE Population Pharmacokinetics model of edoxaban in patients with atrial fibrillation in China, and build a predictive dose model of edoxaban that meets the characteristics of Chinese people. It can provide perfect individualized dosing plan improves clinical efficacy and reduces adverse drug reactions.

Eligibility

Min Age: 20 Years

Plain Language Summary

Simplified for easier understanding

This study looks at how Chinese patients with atrial fibrillation (an irregular heartbeat) process edoxaban (a blood thinner) in their bodies, to help determine the best dosing for this population. **You may be eligible if...** - You are a Chinese patient with atrial fibrillation - You are taking edoxaban as prescribed - You are 18 or older **You may NOT be eligible if...** - You have severe kidney or liver problems - You are taking other blood thinners at the same time - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.